As is clear from these approval timelines, PARP inhibitor therapy in ovarian cancer remains complex, with certain agents approved in certain settings regardless of genomic alterations, some approved only for BRCA1/2 genomic alterations and others approved for germline or somatic alterations in BRCA1/2 or HRD tumors. This evidence concerns the gene BRCA1 and ovarian carcinoma.